Curi Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-18,159
Closed -$523K 101
2023
Q4
$523K Sell
18,159
-4,278
-19% -$129K 0.07% 86
2023
Q3
$744K Sell
22,437
-702
-3% -$24.8K 0.11% 71
2023
Q2
$849K Buy
23,139
+597
+3% +$23.2K 0.11% 77
2023
Q1
$920K Sell
22,542
-7,918
-26% -$342K 0.13% 74
2022
Q4
$1.56M Buy
30,460
+8,130
+36% +$390K 0.22% 61
2022
Q3
$977K Buy
22,330
+17,877
+401% +$869K 0.16% 69
2022
Q2
$233K Buy
4,453
+2,482
+126% +$126K 0.04% 102
2022
Q1
$102K Buy
1,971
+728
+59% +$37.8K 0.02% 159
2021
Q4
$73K Buy
+1,243
New +$61.6K 0.01% 162
2021
Q1
Sell
-196
Closed -$7K 378
2020
Q4
$7K Buy
+196
New +$7.19K 0.01% 288

Other funds holding PFE

Curi Wealth Management's PFE Position: Q1 2024 in Review

Curi Wealth Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 18,159 shares — an estimated $523K sold.

Curi Wealth Management first reported a position in PFE in Q4 2020 and held it in 10 quarters. The position peaked at $1.56M in Q4 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Curi Wealth Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Curi Wealth Management sold 18,159 Pfizer shares in Q1 2024, an estimated $523K.
  • Curi Wealth Management first reported a position in Pfizer in Q4 2020 and held it in 10 quarters.
  • Curi Wealth Management's Pfizer position peaked at $1.56M in Q4 2022.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Curi Wealth Management's 13F filing for Q1 2024.